Inovio Pharmaceuticals, Inc.
INO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001055726
No open-market purchases or sales by Inovio Pharmaceuticals, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $36.1M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Inovio Pharmaceuticals, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 185
- −13 vs. Q1 2022
- Shares held
- 113.4M
- +21.5M (+23.4%) vs. Q1 2022
- Total value
- $196.2M
- −$133.7M (−40.5%) vs. Q1 2022
- New holders
- 21
- 69 more added
- Sold out
- 34
- 37 more reduced
3 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 101 | $36.1M |
| Q1 2026 | 99 | $54.6M |
| Q4 2025 | 101 | $57.5M |
| Q3 2025 | 99 | $48.4M |
| Q2 2025 | 103 | $20.7M |
| Q1 2025 | 108 | $22.2M |
| Q4 2024 | 105 | $24.4M |
| Q3 2024 | 98 | $49.5M |
| Q2 2024 | 96 | $65.1M |
| Q1 2024 | 89 | $56.4M |
| Q4 2023 | 116 | $25.7M |
| Q3 2023 | 127 | $21.6M |
| Q2 2023 | 135 | $32.1M |
| Q1 2023 | 177 | $99.8M |
| Q4 2022 | 186 | $198.5M |
| Q3 2022 | 183 | $200.0M |
| Q2 2022 | 185 | $196.2M |
| Q1 2022 | 201 | $330.4M |
| Q4 2021 | 209 | $428.9M |
| Q3 2021 | 213 | $554.9M |
| Q2 2021 | 211 | $683.1M |
| Q1 2021 | 219 | $693.7M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Inovio Pharmaceuticals, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Moors & Cabot, Inc. | 0 | $0 | 0.00% | −10,850−100.0% | Sold out |
| CIBC Asset Management Inc | 0 | $0 | 0.00% | −10,320−100.0% | Sold out |
| Smith Anglin Financial, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Shell Asset Management Co | 0 | $0 | 0.00% | −9,397−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −4,200−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −1,522−100.0% | Sold out |
| FinTrust Capital Advisors, LLC | 0 | $0 | 0.00% | −598−100.0% | Sold out |
| Money Concepts Capital Corp | 0 | $0 | 0.00% | −152−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −361−100.0% | Sold out |
| Global Retirement Partners, LLC | 0 | $0 | 0.00% | −350−100.0% | Sold out |
| Costello Asset Management, INC | 0 | $0 | 0.00% | −315−100.0% | Sold out |
| Concord Wealth Partners | 0 | $0 | 0.00% | −146−100.0% | Sold out |
| Emfo, LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| RPg Family Wealth Advisory, LLC | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Loring Wolcott & Coolidge Fiduciary Advisors LLP | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Gradient Investments LLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |
| Glassman Wealth Services | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Bogart Wealth, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Investors Research Corp | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Parametric Portfolio Associates LLC | – | – | – | – | Not filed |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |
| SJS Investment Consulting Inc. | – | – | – | – | Not filed |